GlaxoSmithKline P.L.C. and Pfizer Inc. announced a deal that would combine their HIV operations into a new company that would account for almost 20 percent of sales of drugs to fight the virus. In recent years, competitors, most notably Gilead Sciences Inc. and Bristol-Myers Squibb Co., have seized the lead in sales of HIV...
